1.
Invest New Drugs
; 39(1): 237-239, 2021 02.
Article
in English
| MEDLINE
| ID: mdl-32648118
ABSTRACT
Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Subject(s)
Nephritis, Interstitial/chemically induced , Piperidines/adverse effects , Protein Kinase Inhibitors/adverse effects , Quinazolines/adverse effects , Aged , Humans , Male , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Thyroid Neoplasms/drug therapy
2.
